Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma
To evaluate the association between baseline metastatic tumor volume measured on computed tomography (CT) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab as second line or later line therapy.